UNSPSC 51171724: Loperamide hydrochloride

This classification denotes an antidiarrheal agent with the molecular formula C29H33ClN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77TI35393C, chemically known as 4-(p-chlorophenyl)-4-hydroxy-n,n-dimethyl-alpha,alpha-diphenyl-1-piperidinebutyramide monohydrochloride but more generally known as loperamide hydrochloride, which bears US NIH Compound Identifier 71420. European Medicines Agency schedules Loperamide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02969MIG.

UNSPSC 51171724 Loperamide hydrochloride is a Commodity code that encompasses specific pharmaceutical active ingredients and formulations purchased by state and local government entities for operational and public health programs. The recent opportunities tagged to this code show divergence from its nominal scope: the Collin County Community Supervision and Corrections Department RFP covers offender drug testing services (specimen collection, immunoassay screening, and confirmatory testing via LC/MS/MS or GC/MS), while the Texas HHS Commission RFI addresses direct-to-manufacturer prescription procurement strategy, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP solicits generic multi-source pharmaceuticals and OTC products across state and local government facilities in Minnesota and Oregon. None of these opportunities directly specify loperamide hydrochloride as a line item or primary procurement target. The issuing bodies represent state health and human services agencies and county corrections departments, alongside cooperative purchasing vehicles serving multiple state and local jurisdictions.

Recent activity concentrates in Texas and Minnesota. The Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, with proposals due July 23, 2026, for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a term commencing September 1, 2026, with three optional one-year renewals. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs before formal solicitation. MMCAP, administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local facilities. The code shows limited relevant recent activity; the opportunities actually being pursued do not target loperamide hydrochloride explicitly, suggesting this Commodity code may carry a classification mismatch with current state and local procurement demand.